ARCH venture funds disclose 15%+ Sana Biotechnology (SANA) ownership in updated filing

Rhea-AI Filing Summary

Sana Biotechnology, Inc. received an updated ownership report from a group of ARCH venture funds and related entities, plus several individual managers, regarding their holdings of Sana common stock.

As of June 30, 2026, the ARCH-related reporting persons collectively report beneficial ownership or shared power over 45,860,681 shares of Sana common stock, representing 15.3% of the class, based on 299,360,637 shares outstanding as of August 3, 2026. One manager, Robert Nelsen, also holds vested options for 298,591 shares, 1,353 fully vested RSUs, and a related family trust holds 12,500 shares, bringing his reported beneficial ownership to 46,173,125 shares, or 15.4% of the class, assuming exercise of his vested options. The filing details how voting and dispositive power over these shares is shared among multiple ARCH funds, general partners and investment committee members, and includes standard disclaimers that each reporting person only admits beneficial ownership of shares held of record in its or his own name.

Key Figures

ARCH-related shares owned: 45,860,681 shares Ownership percentage: 15.3% Shares outstanding: 299,360,637 shares +5 more

8 metrics

ARCH-related shares owned 45,860,681 shares Shares of Sana common stock reported as beneficially owned with shared power

Ownership percentage 15.3% Portion of Sana common stock class attributed to most reporting persons

Shares outstanding 299,360,637 shares Sana common stock outstanding as of August 3, 2026

Nelsen vested options 298,591 shares Vested options to purchase Sana common stock held by Robert Nelsen

Nelsen vested RSUs 1,353 RSUs Fully vested restricted stock units held by Robert Nelsen

Family trust holdings 12,500 shares Shares of Sana common stock held by Enzo Family Trust of 2015

Nelsen total beneficial stake 46,173,125 shares Beneficial ownership for Robert Nelsen assuming option exercise

Nelsen ownership percentage 15.4% Percentage of Sana common stock class attributed to Robert Nelsen

Key Terms

beneficially own, restricted stock units, dispositive power, record owner, +1 more

5 terms

beneficially own financial

"may be deemed to beneficially own the AVF IX Shares"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

restricted stock units financial

"Nelsen is a holder of vested options to purchase 298,591 shares of Common Stock and 1,353 fully vested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

dispositive power financial

"share the power to direct the disposition and vote of the IX Record Shares"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

record owner financial

"AVF IX is the record owner of 10,667,387 shares of Common Stock"

Powers of Attorney regulatory

"executed by Mark McDonnell pursuant to Powers of Attorney filed as Exhibit 24.0 and Exhibit 24.1"

A power of attorney is a legal document that lets one person give another the authority to act on their behalf for specified tasks, such as handling bank accounts, signing contracts, or making medical decisions. For investors it matters because it determines who can buy, sell, or manage assets and make binding decisions during illness or absence—think of it as appointing a trusted agent to handle your financial and personal paperwork when you cannot. Keepers of these powers can affect ownership, voting, and access to funds.

FAQ

How much of Sana Biotechnology (SANA) do the ARCH funds report owning?

The ARCH-related reporting persons report 45,860,681 shares of Sana common stock, representing 15.3% of the outstanding class, based on 299,360,637 shares outstanding as of August 3, 2026.

Which ARCH entities are reporting ownership in Sana Biotechnology (SANA)?

The report lists multiple ARCH funds and affiliates, including ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., and their related general partners and LLC managers.

What is Robert Nelsen’s reported stake in Sana Biotechnology (SANA)?

Robert Nelsen’s reported beneficial ownership totals 46,173,125 shares, or 15.4% of Sana’s common stock, assuming exercise of 298,591 vested options, plus 1,353 vested RSUs and 12,500 shares held by a family trust.

How is the ownership structure described for Sana Biotechnology (SANA) shares?

Record ownership is held by specific ARCH funds such as AVF IX, AVF IX Overage, AVF X and AVF X Overage, while various ARCH general partner entities and investment committee members may be deemed to share voting and dispositive power.

On what share count is the ownership percentage in Sana Biotechnology (SANA) based?

The ownership percentages are calculated using 299,360,637 shares of Sana common stock outstanding as of August 3, 2026, as reported by the company in its Form 10-Q filed on August 10, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:09 PM Accepted by SEC EDGAR 08/14/2026 - 04:05 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

Sana Biotechnology, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

799566104

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

ARCH Venture Fund IX, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

ARCH Venture Fund IX Overage, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

ARCH Venture Fund X, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

ARCH Venture Fund X Overage, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

ARCH Venture Partners IX, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

ARCH Venture Partners IX Overage, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

ARCH Venture Partners X Overage, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

ARCH Venture Partners X, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

ARCH Venture Partners IX, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

ARCH Venture Partners X, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

Keith Crandell

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

Clinton Bybee

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

Robert Nelsen

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 312,444.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 312,444.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

46,173,125.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.4 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

Steven Gillis

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 799566104

1

Names of Reporting Persons

Kristina Burow

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 45,860,681.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 45,860,681.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Sana Biotechnology, Inc.
(b)	Address of issuer's principal executive offices: 188 East Blaine Street, Suite 350, Seattle, WA 98102
Item 2.
(a)	Name of person filing: ARCH Venture Fund IX, L.P. ("AVF IX"); ARCH Venture Partners IX, L.P. ("AVP IX LP"); ARCH Venture Partners IX, LLC ("AVP IX LLC"); ARCH Venture Fund IX Overage, L.P. ("AVF IX Overage"); ARCH Venture Partners IX Overage, L.P. ("AVP IX Overage GP"); ARCH Venture Fund X, L.P. ("AVF X"); ARCH Venture Partners X, L.P. ("AVP X LP"); ARCH Venture Fund X Overage, L.P. ("AVF X Overage"); ARCH Venture Partners X Overage, L.P. ("AVP X Overage GP"); ARCH Venture Partners X, LLC ("AVP X LLC"); (collectively, the "Reporting Entities" and individually, each a "Reporting Entity"); and Keith Crandell ("Crandell"), Robert Nelsen ("Nelsen") and Clinton Bybee ("Bybee") (collectively, the "Managing Directors" and individually, each a "Managing Director"), and Steven Gillis ("Gillis") and Kristina Burow ("Burow"), along with Nelsen and Crandell, collectively the "Investment Committee"; individually "Committee Members". The Reporting Entities, Managing Directors and the Investment Committee Members collectively are referred to as the "Reporting Persons". The Reporting Persons are filing this report with respect to shares of Common Stock, par value $0.0001 per share (the "Common Stock") of Sana Biotechnology, Inc. (the "Issuer").
(b)	Address or principal business office or, if none, residence: 8755 W. Higgins Road, Suite 1025, Chicago, IL 60631
(c)	Citizenship: Each of AVF IX, AVP IX LP, AVF IX Overage, AVP IX Overage GP, AVF X, AVP X LP, AVF X Overage and AVP X Overage GP are limited partnerships organized under the laws of the State of Delaware. AVP IX LLC and AVP X LLC are each a limited liability company organized under the laws of the State of Delaware. Each Managing Director and Committee Member is a US citizen.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 799566104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: AVF IX is the record owner of 10,667,387 shares of Common Stock (the "AVF IX Shares") as of June 30, 2026. AVP IX LP, as the sole general partner of AVF IX, may be deemed to beneficially own the AVF IX Shares. AVF IX Overage is the record owner of 10,301,250 shares of Common Stock (the "AVF IX Overage Shares") as of June 30, 2026. AVP IX Overage GP, as the sole general partner of AVF IX Overage, may be deemed to beneficially own the AVF IX Overage Shares, combined with AVF IX Shares (the "IX Record Shares"). AVF X is the record owner of 12,446,022 shares of Common Stock (the "AVF X Shares") as of June 30, 2026. AVP X LP, as the sole general partner of AVF X, may be deemed to beneficially own the AVF X Shares. AVF X Overage is the record owner of 12,446,022 shares of Common Stock (the "AVF X Overage Shares") as of June 30, 2026. AVP X Overage GP, as the sole general partner of AVF X Overage, may be deemed to beneficially own the AVF X Overage Shares, combined with AVF X Shares (the "X Record Shares"). AVP IX LLC, as the sole general partner of AVP IX LP and AVP IX Overage GP, may be deemed to beneficially own the IX Record Shares. As managing directors of AVP IX LLC, each Managing Director may also be deemed to share the power to direct the disposition and vote of the IX Record Shares. AVP X LLC, as the sole general partner of AVP X LP and AVP X Overage GP, may be deemed to beneficially own the X Record Shares. As Investment Committee Members of AVP X LLC, each Committee Member may also be deemed to share the power to direct the disposition and vote of the X Record Shares. In addition, as of June 30, 2026, Nelsen is a holder of vested options to purchase 298,591 shares of Common Stock (the "Vested Option Shares") and 1,353 fully vested restricted stock units ("RSUs") and Enzo Family Trust of 2015, the beneficiaries of which are members of Nelsen's family, holds 12,500 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of such shares of Common Stock except for the shares, if any, such Reporting Person holds of record.
(b)	Percent of class: The information required by Item 4(b) is incorporated by reference to Row 11 of the cover pages hereto. The percentages set forth on the cover pages for each Reporting Person (other than Nelsen) are based upon 299,360,637 shares of Common Stock outstanding as of August 3, 2026, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2026, and, in the case of Nelsen, assumes the exercise of the Vested Option Shares.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See row 5 of the cover pages.
	(ii) Shared power to vote or to direct the vote: See row 6 of the cover pages.
	(iii) Sole power to dispose or to direct the disposition of: See row 7 of the cover pages.
	(iv) Shared power to dispose or to direct the disposition of: See row 8 of the cover pages.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ARCH Venture Fund IX, L.P.

Signature:	/s/ ARCH Venture Partners IX, L.P.
Name/Title:	its General Partner
Date:	08/14/2026

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	08/14/2026

ARCH Venture Fund IX Overage, L.P.

Signature:	/s/ ARCH Venture Partners IX Overage, L.P.
Name/Title:	its General Partner
Date:	08/14/2026

Signature:	/s/ ARCH Venture Partners IX, LLC
Name/Title:	its General Partner
Date:	08/14/2026

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	08/14/2026

ARCH Venture Fund X, L.P.

Signature:	/s/ ARCH Venture Partners X, L.P.
Name/Title:	its General Partner
Date:	08/14/2026

Signature:	/s/ ARCH Venture Partners X, LLC
Name/Title:	its General Partner
Date:	08/14/2026

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	08/14/2026

ARCH Venture Fund X Overage, L.P.

Signature:	/s/ ARCH Venture Partners X Overage, L.P.
Name/Title:	its General Partner
Date:	08/14/2026

Signature:	/s/ ARCH Venture Partners X, LLC
Name/Title:	its General Partner
Date:	08/14/2026

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	08/14/2026

ARCH Venture Partners IX, L.P.

Signature:	/s/ ARCH Venture Partners IX, LLC
Name/Title:	its General Partner
Date:	08/14/2026

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	08/14/2026

ARCH Venture Partners IX Overage, L.P.

Signature:	/s/ ARCH Venture Partners IX, LLC
Name/Title:	its General Partner
Date:	08/14/2026

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	08/14/2026

ARCH Venture Partners X Overage, L.P.

Signature:	/s/ ARCH Venture Partners X, LLC
Name/Title:	its General Partner
Date:	08/14/2026

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	08/14/2026

ARCH Venture Partners X, L.P.

Signature:	/s/ ARCH Venture Partners X, LLC
Name/Title:	its General Partner
Date:	08/14/2026

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	08/14/2026

ARCH Venture Partners IX, LLC

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	08/14/2026

ARCH Venture Partners X, LLC

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	08/14/2026

Keith Crandell

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Keith Crandell
Date:	08/14/2026

Clinton Bybee

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Clinton Bybee
Date:	08/14/2026

Robert Nelsen

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Robert Nelsen
Date:	08/14/2026

Steven Gillis

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Steven Gillis
Date:	08/14/2026

Kristina Burow

Signature:	/s/ Mark McDonnell
Name/Title:	Mark McDonnell as Attorney-in-Fact for Kristina Burow
Date:	08/14/2026

Comments accompanying signature: * This Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney filed as Exhibit 24.0 and Exhibit 24.1 to the Form 3 relating to the beneficial ownership of shares of Sana Biotechnology, Inc. by certain of the Reporting Persons filed with the Securities and Exchange Commission on February 3, 2021 and incorporated herein in its entirety by reference and Powers of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Gossamer Bio, Inc. by certain of the Reporting Persons filed with the Securities and Exchange Commission on February 7, 2019 and incorporated herein in its entirety by reference.